*********************************
There is now a CONTENT FREEZE for Mercury while we switch to a new platform. It began on Friday, March 10 at 6pm and will end on Wednesday, March 15 at noon. No new content can be created during this time, but all material in the system as of the beginning of the freeze will be migrated to the new platform, including users and groups. Functionally the new site is identical to the old one. webteam@gatech.edu
*********************************
Sang-Eon Park
BioE Ph.D. Defense Presentation
2:00 pm, Friday, Oct. 25th, 2019
Emory University WMRB 5101
Advisor:
Robert E. Gross, M.D. Ph.D. (Georgia Institute of Technology/Emory University)
Committee:
Babak Mahmoudi, Ph.D. (Georgia Institute of Technology/Emory University)
Christopher J. Rozell, Ph.D. (Georgia Institute of Technology)
John T. Gale, Ph.D. (Emory University)
Joseph R. Manns, Ph.D. (Emory University)
Optimizing neuromodulation for temporal lobe epilepsy treatment based on a surrogate neural state model
Temporal lobe epilepsy is the most prevalent form of medication-resistant epilepsy, and current electrical stimulation therapy has not been able to accomplish the goal of seizure-freedom. This underscores the need for a new target and a different approach with more effective neuromodulation for epilepsy treatment. The projections from the medial septum (MS) and its regulatory role on the hippocampus make it an attractive neuromodulation target. Optogenetics enables selective excitation or inhibition of individual genetically-defined neuronal subpopulations, and thus provides a chance to find a better target among neuronal subpopulations for inducing a greater therapeutic effect. I have exhaustively explored the effect of exciting or inhibiting different neuronal subpopulations in the normal rat medial septum by using optogenetic stimulation. As a result, MS optogenetic stimulation using hSynapsin promoter in combination with Channelrhodopsin-2 was well suited for modulating electrophysiological activity of the hippocampus.